NCT04265872 2026-02-12
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
Baylor Research Institute
Phase EARLY_PHASE1 Recruiting
Baylor Research Institute
Ohio State University Comprehensive Cancer Center
Canadian Cancer Trials Group
Peking University